Table 1.
Characteristics of Stage IV Melanoma Patients
| ID | Sex | Age (yrs) | ICI Therapy | Cardiovascular Risk Factors |
|---|---|---|---|---|
| 1 | M | 56 | Ipilimumab (IT), nivolumab (intravenous) | None |
| 2 | M | 62 | Ipilimumab (IV), nivolumab (intravenous) | None |
| 3 | F | 54 | Ipilimumab (IT), nivolumab (intravenous) | Hypertension |
| 4 | F | 46 | Ipilimumab (IV), nivolumab (intravenous) | None |
| 5 | F | 57 | Ipilimumab (IT), nivolumab (intravenous) | None |
| 6 | M | 37 | Ipilimumab (IT), nivolumab (intravenous) | Hypertension |
| 7 | M | 65 | Ipilimumab (IT), nivolumab (intravenous) | Hypertension, dyslipidemia |
| 8 | F | 52 | Ipilimumab (IT), nivolumab (intravenous) | None |
| 9 | M | 48 | Ipilimumab (IT), nivolumab (intravenous) | Tobacco smoking |
| 10 | F | 50 | Pembrolizumab | Hypertension |
IT = intratumoral.